Medanta Business Model Canvas

Medanta maintains contracts with insurers and TPAs to enable cashless admissions and streamlined preauthorization, aligning workflows to reduce administrative delays. Standardized packages and tariffs shorten claim turnaround and improve predictability for payers. Medanta shares de-identified outcomes data to enable outcomes-based arrangements, leveraging scale from public programs covering over 500 million lives (2024). The hospital co-creates wellness and disease-management plans for covered populations.

Partner with OEMs for imaging/ICU tech to secure ≥99.5% uptime; global medtech revenue ~$595B (2024). Align with pharma/diagnostics to stabilize cold-chain and lower unit costs; India produced largest vaccine volume (2024). Contract insurers/TPAs and academic centers to enable cashless care, outcomes data sharing and research (CTRI>1,200 trials; public schemes cover >500M lives, 2024).

Coordinate admissions, billing, discharge and post-acute follow-ups across Medanta’s 1,250-bed flagship Gurugram campus to reduce length-of-stay and readmissions. Provide navigation, concierge and interpreter services to streamline patient flow and increase outpatient-to-admission conversion. Collect feedback via NPS with systematic close-the-loop actions, and operate formal grievance redressal and service-recovery protocols to protect clinical and financial outcomes.

Deliver high‑acuity surgery, ICU and advanced therapies across cardiology, oncology, neurosciences and ortho; operate labs/imaging (95% labs <4h, imaging <24h); manage 1,250‑bed Gurugram campus to reduce LOS/readmissions; run trials, training, CMEs and telemedicine (India telemedicine market ~USD 2.8bn in 2024) with eICU and integrated digital care.

Medanta's technology stack integrates EMR/EHR, PACS, LIS and HIS into a single care-delivery platform to streamline diagnostics and workflows across specialties.

Interoperability follows national standards and layered cybersecurity safeguards (encryption, IAM, SOC monitoring) to protect patient data and regulatory compliance.

Centralized data warehouses and analytics drive outcomes measurement and cost optimization; telehealth and remote-monitoring platforms handled a 2024 increase in virtual consults supporting continuity of care.

Specialist medical talent, multidisciplinary teams and robust credentialing anchor Medanta's care model; flagship capacity ~1,250 beds with optimized occupancy ≈75% supports high-acuity volumes. Integrated EMR/PACS/LIS, centralized analytics and layered cybersecurity enable outcomes tracking and surge resilience; telehealth volumes rose in 2024 supporting continuity. NABH and JCI accreditations, 15 years of operation (since 2009) and insurer networks covering >500 million beneficiaries drive referrals.

Integrated patient journey links screening to rehabilitation under a single care plan, leveraging Medanta’s network of over 1,000 beds to streamline referrals and capacity. Digital tools enable appointments, reports and payments via a unified portal and app. Post-discharge follow-ups and remote monitoring reduce complications and enable early intervention. Personalized care plans are mapped to patient goals and outcomes metrics.

Medanta’s 1,250-bed Medicity (est. 2009) delivers integrated diagnostics, surgery and critical care with coordinated multidisciplinary teams and shorter LOS reported in institutional audits. Network exceeds 1,000 beds (2024) with teleconsults, outreach clinics and insurer tie-ups to improve access and affordability. NABH/NABL accreditations, published outcomes and routine audits support quality and continuous improvement.

Medanta offers membership plans for preventive checks and chronic care with bundled screening packages and vaccination drives integrated into corporate and community outreach. Rewards programs incentivize medication adherence and referrals, while EMR- and analytics-driven personalization tailors care pathways and reminder schedules. Programs leverage patient data to optimize follow-up intervals and preventive interventions.

Dedicated care coordinators, 24/7 centralized triage and automated reminders drive continuity and adherence; 2024 evidence links care coordination to ~20% fewer readmissions. Memberships, corporate RMs and empanelment streamline revenue and cashless access while outreach camps and support groups boost referrals and retention. Standardized pre-/post-op checklists and tele-follow ups reduce fragmentation and complications.

Liaison teams connect with GPs and specialists to channel referrals, maintaining a network that drives roughly 40% of tertiary-case inflow as of 2024. Regular CME programs and joint case discussions reinforce clinical trust and increase specialist-to-hospital conversion rates. A streamlined digital referral intake with KPI-driven feedback loops reduces turnaround time and referral leakage. Targeted outreach in tier-2/3 markets captures rising demand and expands referral catchment.

Medanta channels combine hospital campuses (1,000+ beds across 5 locations in 2024) with digital platforms (telemedicine market $1.62B in 2024; UPI >100B txns) for bookings, remote consults and payments. Referral liaison teams drive ~40% of tertiary inflow; corporate/insurer empanelments, employee health programs and community camps expand volume. PR, regional-language outreach and CME reinforce trust and conversion.

Patients from neighboring countries and the Indian diaspora (over 20,000 international patients at Medanta in 2024) seek advanced procedures at competitive costs, driving bundled-pricing packages and visa facilitation services. They require translators, concierge coordination, and bundled pricing that combines surgery, diagnostics and stay; many bookings cite cost savings of 40–60% versus Western markets. Expectation for white-glove concierge and end-to-end logistics is high.

Complex tertiary patients (cardiac, neuro, oncology, ortho) prefer outcome-driven, cashless-insurer and concierge packages; Medanta served ~20,000 international patients in 2024 and draws from Gurugram catchment ~1.5M. India population ~1.428B (2024) fuels rising demand; NCDs ~74% of deaths. Referrers expect 24-hour turnaround and co-management with measurable outcomes.

Drugs, implants, stents, reagents and disposables constitute a major recurring cost line, managed through centralized inventory and cold-chain systems to prevent stockouts and spoilage. Long-term vendor contracts and purchase-volume agreements reduce unit costs and enable JIT delivery, while strict wastage-control protocols and batch-level tracking cut losses. Compliance with regulatory and quality standards adds certification, testing and audit expenses integrated into procurement budgets.

Personnel ~50% of Opex; specialist pay INR 1.5–2.5 lakh/mo, nurses 25–35k/mo (2024). Capex: OT suite INR 3–15 crore, PET‑CT/linac INR 40–80 crore; AMCs 2–4% revenue. Consumables and implants drive recurring costs; centralized procurement and vendor contracts trim 5–15% of unit costs. IT, compliance, utilities and CSR (2%) form material fixed overheads.

Medanta’s in-house pharmacy and procedure-linked implants generate steady ancillary revenue, tapping a global orthopedic implants market valued at about USD 54 billion in 2023. Margin management via formulary control and bulk procurement improves gross margins, while consistent availability raises adherence and procedure uptake. Transparent pricing (itemized pharmacy and implant lists) strengthens patient trust and drives repeat referrals.

Medanta revenue mixes high-ARPOB inpatient/surgical care with bundled pricing, outpatient/diagnostics (India diagnostics ~USD14B 2024), pharmacy/implants (global implants ~USD54B 2023) and medical tourism (~USD82B 2024). Corporate contracts give 10–25% discounts, SLAs 24–72h and outcomes bonuses 5–10%, while care-pathways shorten LOS and raise bed turnover.